Compare · CRON vs PXMD
CRON vs PXMD
Side-by-side comparison of Cronos Group Inc. (CRON) and PaxMedica Inc. (PXMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CRON and PXMD operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- CRON carries a market cap of $1.03B.
- Over the past year, CRON is up 46.4% and PXMD is up 0.0% - CRON leads by 46.4 points.
- CRON has hit the wire 3 times in the past 4 weeks while PXMD has been quiet.
- CRON has more recent analyst coverage (11 ratings vs 0 for PXMD).
- Company
- Cronos Group Inc.
- PaxMedica Inc.
- Price
- $2.68+3.47%
- $0.72-3.73%
- Market cap
- $1.03B
- -
- 1M return
- +2.29%
- +0.00%
- 1Y return
- +46.45%
- +0.00%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- News (4w)
- 3
- 0
- Recent ratings
- 11
- 0
Cronos Group Inc.
Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. It sells cannabis and cannabis products, including dried cannabis, pre-rolls, and cannabis extracts through wholesale and direct-to-client channels under its wellness platform, PEACE NATURALS; and operates under two adult-use brands, COVE and Spinach. The company also exports dried cannabis and cannabis oils to Germany, Israel, and Australia. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.
Latest CRON
- SEC Form DEFA14A filed by Cronos Group Inc.
- SEC Form DEF 14A filed by Cronos Group Inc.
- Cronos Group Inc. to Hold 2026 First Quarter Earnings Conference Call on May 11, 2026
- SEC Form 4 filed by Shlimak Anna
- Officer Doucet Terrence Gregory Joseph converted options into 23,897 shares and covered exercise/tax liability with 12,276 shares, increasing direct ownership by 12% to 105,190 units (SEC Form 4)
- Officer Weigensberg Arye converted options into 24,236 shares, increasing direct ownership by 13% to 208,437 units (SEC Form 4)
- Officer Gorenstein Michael Ryan converted options into 324,540 shares and covered exercise/tax liability with 127,706 shares, increasing direct ownership by 2% to 13,213,017 units (SEC Form 4)
- Officer Shlimak Anna converted options into 45,226 shares and covered exercise/tax liability with 16,354 shares, increasing direct ownership by 9% to 339,933 units (SEC Form 4)
- Chief Growth Officer Jacobson Jeffrey David converted options into 59,191 shares and covered exercise/tax liability with 22,552 shares, increasing direct ownership by 8% to 484,681 units (SEC Form 4)
- Officer Buggy Shannon covered exercise/tax liability with 9,202 shares and converted options into 20,938 shares, increasing direct ownership by 8% to 166,879 units (SEC Form 4)
Latest PXMD
- PaxMedica Inc. filed SEC Form 8-K: Leadership Update
- PaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other Conditions
- Amendment: SEC Form SC 13G/A filed by PaxMedica Inc.
- SEC Form NT 10-Q filed by PaxMedica Inc.
- SEC Form EFFECT filed by PaxMedica Inc.
- SEC Form S-1 filed by PaxMedica Inc.
- SEC Form 10-Q filed by PaxMedica Inc.
- PaxMedica Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Financial Statements and Exhibits
- PaxMedica Secures Immediate Exercise of Warrants
- PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection